Thanks Denial.
I will be in touch with Paradigm about the trial and some other questions I have.
From my read the initial phase 3 (oa 11) did not meet primary end points but their extension study oa o7 did meet its primary "objective" and did show structural benefit over placebo..
It seems we are obviously way more advanced and our target of KL 3 and 4 is different to where their drug shows most benefit KL2.
I assume they would also need to start a whole new FDA aproved phase 3. So it kooks like we are good...
I also noticed another early trial for hand and finger joint OA with another repurposed drug called Talarozole. Different specific indication and early days but worth noting
https://www.medicalnewstoday.com/articles/new-repurposed-drug-talarozole-hand-osteoarthritis
- Forums
- ASX - By Stock
- PAR
- AGM 2024 - QUESTIONS
AGM 2024 - QUESTIONS, page-45
-
- There are more pages in this discussion • 107 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
|
|||||
Last
25.5¢ |
Change
-0.005(1.92%) |
Mkt cap ! $89.19M |
Open | High | Low | Value | Volume |
27.0¢ | 27.0¢ | 25.5¢ | $261.4K | 990.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9999 | 25.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
26.0¢ | 9445 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9999 | 0.255 |
5 | 259000 | 0.250 |
4 | 96000 | 0.245 |
9 | 261374 | 0.240 |
5 | 71970 | 0.235 |
Price($) | Vol. | No. |
---|---|---|
0.260 | 9445 | 1 |
0.275 | 44000 | 2 |
0.280 | 35900 | 3 |
0.285 | 6729 | 2 |
0.290 | 60000 | 2 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online